Centessa Pharmaceuticals Aktie - 0ACX

Rendering Error

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

Gebot

0,00

Fragen

0,00

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Marktkapitalisierung

Handelsende

0,00

Handelsbeginn

Letzte Trade

15.6543

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

0,00

Dividendenrendite

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

Erlöse

6,85M

Nettogewinn

-151,09M

Sektor

Coml Physical, Biologcl Resh

Branche

Coml Physical, Biologcl Resh

Website

www.centessa.com

Hauptsitz

Cheshire, Gbr

Gegründet

Centessa Pharmaceuticals Plc is listed in the Coml Physical, Biologcl Resh sector of the Londoner Börse with ticker 0ACX. The last closing price for Centessa Pharmaceuticals was US$0,00. Over the last year, Centessa Pharmaceuticals shares have traded in a share price range of US$ 0,00 to US$ 0,00.

Centessa Pharmaceuticals currently has 0 shares in issue.

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update Announced additional interim data...

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 12...

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 11, 2024 (GLOBE...

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived...

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 Company advancing pipeline of potential...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0ACX - Frequently Asked Questions (FAQ)

What is the current Centessa Pharmaceuticals share price?

The current share price of Centessa Pharmaceuticals is US$ 0,00

What is the 1 year trading range for Centessa Pharmaceuticals share price?

Centessa Pharmaceuticals has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the reporting currency for Centessa Pharmaceuticals?

Centessa Pharmaceuticals reports financial results in USD

What is the latest annual turnover for Centessa Pharmaceuticals?

The latest annual turnover of Centessa Pharmaceuticals is USD 6,85M

What is the latest annual profit for Centessa Pharmaceuticals?

The latest annual profit of Centessa Pharmaceuticals is USD -151,09M

What is the registered address of Centessa Pharmaceuticals?

The registered address for Centessa Pharmaceuticals is 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE, WA14 2DT

What is the Centessa Pharmaceuticals website address?

The website address for Centessa Pharmaceuticals is www.centessa.com

Which industry sector does Centessa Pharmaceuticals operate in?

Centessa Pharmaceuticals operates in the COML PHYSICAL, BIOLOGCL RESH sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AMGOAmigo Holdings Plc	0,475p (72,73%)	11,81M
BEMBeowulf Mining Plc	22,00p (25,71%)	104,2k
WSGWestminster Group Plc	1,30p (23,81%)	1,4M
BLOEBlock Energy Plc	1,00p (21,21%)	11,06M
SMLStrategic Minerals Plc	0,30p (20,00%)	11,23M
SSTScottish Oriental Smaller Companies Trust Plc	290,00p (-95,96%)	76,08k
ONCOncimmune Holdings Plc	1,40p (-43,78%)	1,57M
BMTOBraime Group Plc	1.350,00p (-20,59%)	547
PYXPyx Resources Limited	1,97p (-19,76%)	398,74k
MGAMMorgan Advanced Materials Plc	214,50p (-16,21%)	8,59M
TRPTower Resources Plc	0,0245p (6,52%)	775,51M
UKOGUk Oil & Gas Plc	0,01125p (-4,26%)	434,61M
TW.Taylor Wimpey Plc	114,25p (2,05%)	345,64M
LLOYLloyds Banking Group Plc	72,32p (0,84%)	344,78M
PREMPremier African Minerals Limited	0,0205p (-11,26%)	300,49M

Rendering Error

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Centessa Pharmaceuticals Plc (0ACX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Centessa Pharmaceuticals Plc

0ACX Neueste Nachrichten

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Frequently Asked Questions (FAQ)

Beweger

0ACX Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Centessa Pharmaceuticals Plc (0ACX) Börsenkurse

Centessa Pharmaceuticals Plc (0ACX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Centessa Pharmaceuticals Plc

0ACX Neueste Nachrichten

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Frequently Asked Questions (FAQ)

Beweger

0ACX Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE